|Articles|February 2, 2002

FDA gives nod to etanercept for psoriatic arthritis Tx

Seattle - Already approved for the treatment of rheumatoid arthritis,the FDA granted approval that extends etanercept's (Enbrel) use to the treatmentof psoriatic arthritis for the one million American sufferers.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Latest CME

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Video

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Video

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Video

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Video

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Video

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Multimedia

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Video

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Video

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

FDA gives nod to etanercept for psoriatic arthritis Tx

Related Content

Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging

Digital Twins in Dermatology: Your Patient’s Virtual Double Is Coming

Quality of Life in CSU Shaped by More Than Skin Symptoms

KT-621 in Atopic Dermatitis: What Early EASI and Pruritus Data Show

Breakout Bulletin: June 7-12

Latest CME

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Trending on Dermatology Times

Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show

FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years

Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease

Oral STAT6 Degrader KT-621 Shows Biologic-Comparable Activity in Atopic Dermatitis

Lebrikizumab Earns FDA Approval for Less Frequent, Every-8-Week Maintenance Dosing in AD